AstraZeneca vax 92% effective against Delta variant
The higher efficacy against severe disease and hospitalisation is supported by recent data showing strong T-cell response to Covid-19 Vaccine AstraZeneca, which should correlate with high and durable protection
image for illustrative purpose
New Delhi: ASTRAZENECA said new data from Public Health England (PHE) demonstrated Covid-19 vaccine AstraZeneca, offers high levels of protection against the Delta variant (B.1.617.2; formerly the 'Indian variant'). AstraZeneca vaccine is used in India as Covishield. Real world data from PHE, demonstrated two doses of Covid-19 vaccine AstraZeneca are 92 per cent effective against hospitalisation due to the Delta variant and showed no deaths among those vaccinated. The vaccine also showed a high level of effectiveness against the Alpha variant (B.1.1.7; formerly the 'Kent' variant) with an 86 per cent reduction of hospitalisations and no deaths reported.
The higher efficacy against severe disease and hospitalisation is supported by recent data showing strong T-cell response to Covid-19 Vaccine AstraZeneca, which should correlate with high and durable protection.
Mene Pangalos, Executive Vice President, and BioPharmaceuticals R&D, said: "This real world evidence shows that Covid-19 Vaccine AstraZeneca provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. The data show that the vaccine will continue to have a significant impact around the world given that it continues to account for the overwhelming majority of supplies to India and the Covax facility."
The analysis included 14,019 cases of the Delta variant – 122 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England.
